L. G. Paz-Ares Et Al. , "Durvalumab +/- tremelimumab plus platinum-etoposide in first-line extensive-stage SCLC (ES-SCLC): Updated results from the phase III CASPIAN study.," JOURNAL OF CLINICAL ONCOLOGY , vol.38, no.15, 2020
Paz-Ares, L. G. Et Al. 2020. Durvalumab +/- tremelimumab plus platinum-etoposide in first-line extensive-stage SCLC (ES-SCLC): Updated results from the phase III CASPIAN study.. JOURNAL OF CLINICAL ONCOLOGY , vol.38, no.15 .
Paz-Ares, L. G., Dvorkin, M., Chen, Y., Reinmuth, N., Hotta, K., Trukhin, D., ... Statsenko, G.(2020). Durvalumab +/- tremelimumab plus platinum-etoposide in first-line extensive-stage SCLC (ES-SCLC): Updated results from the phase III CASPIAN study.. JOURNAL OF CLINICAL ONCOLOGY , vol.38, no.15.
Paz-Ares, Luis Et Al. "Durvalumab +/- tremelimumab plus platinum-etoposide in first-line extensive-stage SCLC (ES-SCLC): Updated results from the phase III CASPIAN study.," JOURNAL OF CLINICAL ONCOLOGY , vol.38, no.15, 2020
Paz-Ares, Luis G. Et Al. "Durvalumab +/- tremelimumab plus platinum-etoposide in first-line extensive-stage SCLC (ES-SCLC): Updated results from the phase III CASPIAN study.." JOURNAL OF CLINICAL ONCOLOGY , vol.38, no.15, 2020
Paz-Ares, L. G. Et Al. (2020) . "Durvalumab +/- tremelimumab plus platinum-etoposide in first-line extensive-stage SCLC (ES-SCLC): Updated results from the phase III CASPIAN study.." JOURNAL OF CLINICAL ONCOLOGY , vol.38, no.15.
@article{article, author={Luis G. Paz-Ares Et Al. }, title={Durvalumab +/- tremelimumab plus platinum-etoposide in first-line extensive-stage SCLC (ES-SCLC): Updated results from the phase III CASPIAN study.}, journal={JOURNAL OF CLINICAL ONCOLOGY}, year=2020}